Cingulate (CING) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed vTv Therapeutics (VTVT) over the past year, gaining 27.8% versus a loss of 47.5%. Cingulate is the larger company by market cap ($67.5 million vs $62.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | VTVT |
|---|---|---|
| Share price | $4.51 | $15.51 |
| Market cap | $67.48M | $62.22M |
| 1-day change | -14.26% | -5.20% |
| YTD return | +3.92% | -61.22% |
| 1-year return | +27.76% | -47.53% |
| 5-year return | — | -71.06% |
| EPS (TTM) | $-2.67 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-22.45M | $-26.97M |
| 52-week high | $11.89 | $44.00 |
| 52-week low | $3.16 | $15.47 |
| Distance from 52-week high | -62.07% | -64.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +370.07% | +261.06% |
| Average volume | 178.82K | 33.07K |
| Shares outstanding | 14.96M | 4.01M |
| Employees | 14 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed VTVT by 75.3 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
CING vs VTVT FAQ
Which is bigger, Cingulate or vTv Therapeutics?
Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $62.22M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, CING or VTVT?
CING returned +27.76% over the past 12 months, compared with -47.53% for VTVT (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.